<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">The main proteinase 3CL
 <sup>pro</sup>, is one of the primary targets for development in an antiviral drug therapies, as it plays a critical role in the viral replication [
 <xref ref-type="bibr" rid="CR13">13</xref>]. K11777, camostat and EST, are cysteine protease inhibitors, which have been shown to inhibit SARS-CoV 3CL
 <sup>pro</sup> replication in cell culture conditions [
 <xref ref-type="bibr" rid="CR14">14</xref>, 
 <xref ref-type="bibr" rid="CR15">15</xref>]. Recent release of the high-resolution crystal structure for the main proteinase 3CL
 <sup>pro</sup> (Protein Data Bank, PDB ID: 6Y2G), describing an additional amide bond with the Î±-ketoamide inhibitor pyridone ring to enhance the half-life of the compound in plasma [
 <xref ref-type="bibr" rid="CR16">16</xref>] is suggested to accelerate the targeted drug discovery efforts. Two HIV-1 proteinase inhibitors, lopinavir and ritonavir, have been considered to target SARS-CoV [
 <xref ref-type="bibr" rid="CR17">17</xref>]. Interestingly, the substrate binding cleft is located between domains I and II of both SARS-CoV 3CL
 <sup>pro</sup> and SARS-CoV-2 3CL
 <sup>pro</sup> enzymes [
 <xref ref-type="bibr" rid="CR16">16</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
